Capital Analysts, LLC Rocket Pharmaceuticals, Inc. Transaction History
Capital Analysts, LLC
- $2.45 Billion
- Q3 2024
A detailed history of Capital Analysts, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital Analysts, LLC holds 175 shares of RCKT stock, worth $2,058. This represents 0.0% of its overall portfolio holdings.
Number of Shares
175Holding current value
$2,058% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RCKT
# of Institutions
209Shares Held
93.2MCall Options Held
319KPut Options Held
70.3K-
Rtw Investments, LP New York, NY17.7MShares$208 Million5.21% of portfolio
-
Wellington Management Group LLP Boston, MA11.2MShares$132 Million0.04% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$72.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.54MShares$65.1 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.49MShares$52.8 Million0.39% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $890M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...